Acute Myeloid Leukemia (AML) - Dynamic Market Forecast to 2026

  • ID: 4473071
  • Report
  • 72 pages
  • GlobalData
1 of 3
Acute Myeloid Leukemia (AML) - Dynamic Market Forecast to 2026

Summary

Acute Myeloid Leukemia (AML) is a disease that has been characterized by a stagnant pipeline and, consequently, the treatment paradigm has not substantially changed over time. Since the 1970s, the standard of care in newly diagnosed fit patients has been a chemotherapy bases 7 + 3 induction regimen (seven days of cytarabine + three days of an anthracycline), aimed at achieving a complete hematologic remission (CR), followed by consolidation therapy with cytarabine, or an allogeneic hematopoietic cell transplantation (HCT). In the last decade, a better understanding of the molecular basis of AML has encouraged the development of new targeted therapies, and this led to the launch of the first targeted agents in 2017. The Dynamic Market Forecast is designed to help clients stay abreast of the latest news in the AML space, including regulatory, commercial, and clinical events as well as understand how all of these events will impact the projected market forecast.

Scope

Key events covered in the Dynamic Market Forecast include:
  • Regulatory filings
  • Approval decisions
  • Pricing changes
  • Patent litigation
  • Clinical trial data announcements
  • Clinical trial failures
  • Clinical trial timeline updates
Components of the slide deck include:
  • Timeline of market-impacting events
  • Key clinical trial landscape updates
  • Conference coverage
  • Detailed analysis of the most impactful events, including new primary research to gain Key Opinion Leader perspective
  • Overview of updates to the forecast model based on anticipated future impact of events
  • Forward-looking events calendar listing expected key updates to the AML competitive space through December 2018
Reasons to buy
  • Recent Regulatory Events
  • Recent Commercial Events
  • Recent Clinical Events
  • New SOC expected for elderly t-AML and AML-MRC patients
  • Adoption of the First FLT3 Inhibitor, Rydapt, in the US and EU
  • Lack of Competition in the IDH+ AML Market Segment Benefits Celgene and Agios
  • US Approval of the First CD33 Targeting Agent, Mylotarg
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1. Dynamic Market Forecast Overview
1.1 Related Reports
1.2 Upcoming Related Reports

2. Executive Summary
2.1 Key Updates to AML Market Dynamics
2.2 Key Events in Update 11-
2.3 Updates to Treatment Algorithms 13-
2.4 Updates to Pipeline Competitive Assessment 15-
2.4 Market Insight on Key Events

3. Conference Coverage - ASH
3.1 Selected Abstracts ASH2017 - AML 19-

4. Event 1: New SOC expected for elderly t-AML and AML-MRC patients
4.1 Key Updates to the Frontline Setting - Elderly Patients
4.2 Jazz, Vyxeos (CPX-351) 23-
4.3 What Do Physicians Think?
4.4 Summary/Trends
4.5 Sources

5. Event 2: Adoption of the First FLT3 Inhibitor, Rydapt, in the US and EU
5.1 Key Updates About the Use of FLT3 Inhibitors in the First- Line Setting
5.2 Competitive Landscape of FLT3 Inhibitors in AML
5.3 Novartis, Rydapt (midostaurin)
5.4 What Do Physicians Think?
5.5 Arog, crenolanib
5.6 Astellas, gilteritinib
5.7 What Do Physicians Think?
5.8 Summary/Trends
5.9 Sources

6. Event 3: Lack of Competition in the IDH+ AML Market Segment Benefits Celgene and Agios
6.1 Key Updates in IDH+ AML
6.2 Agios/Celgene, Idhifa 40-
6.3 Agios, ivosidenib 42-
6.4 What Do Physicians Think?
6.5 Summary/Trends
6.6 Sources

7. Event 4: US Approval of the First CD33 Targeting Agent, Mylotarg
7.1 Key Updates on Mylotarg
7.2 Pfizer, Mylotarg (gemtuzumab ozogamicin)
7.3 What Do Physicians Think?
7.4 Additional Clinical Trial Updates- CD33+
7.5 Summary/Trends
7.6 Sources

8. Additional Events
8.1 Takeda, pevonedistat
8.2 What Do Physicians Think?

9. Other Events of Interest
9.1 Various Developers
9.2 Sources

10. Events Calendar
10.1 Key Events Expected to Occur in 2018

11. Appendix
11.1 Methodology
11.2 Primary Research 65-
11.3 About the Authors 67-
11.4 About
11.5 Contact
11.6 Disclaimer
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll